keyword
MENU ▼
Read by QxMD icon Read
search

treatment of schizophrenia

keyword
https://www.readbyqxmd.com/read/28742394/assessment-of-proteomic-measures-across-serious-psychiatric-illness
#1
S Charles Schulz, Shauna Overgaard, David J Bond, Rajesh Kaldate
The diagnoses of serious psychiatric illnesses, such as schizophrenia, schizoaffective disorder, and bipolar disorder, rely on the subjective recall and interpretation of often overlapping symptoms, and are not based on the objective pathophysiology of the illnesses. The subjectivity of symptom reporting and interpretation contributes to the delay of accurate diagnoses and limits effective treatment of these illnesses. Proteomics, the study of the types and quantities of proteins an organism produces, may offer an objective biological approach to psychiatric diagnosis...
2017: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/28742291/evaluating-the-effect-of-the-changes-in-fda-guidelines-for-clozapine-monitoring
#2
Ryan S Sultan, Mark Olfson, Christoph U Correll, Erica J Duncan
BACKGROUND: Concerns exist that clozapine is underutilized in the management of treatment-resistant schizophrenia. Although a 2015 change in the US Food and Drug Administration (FDA) monitoring recommendations lowered the threshold of the absolute neutrophil count for treatment interruption from 1,500/μL to 1,000/μL and removed white blood cell count thresholds from the monitoring algorithm, the implications of this policy change on clozapine interruptions remain unknown. METHODS: We analyzed outpatient prescribing records for antipsychotic medications in the Veterans Integrated Service Network 7 (VISN 7) database between 1999 and 2012 to assess the potential impact of the recent changes in FDA neutropenia monitoring recommendations on clozapine treatment discontinuation...
July 18, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28742260/incorporating-patient-preferences-into-estimation-of-optimal-individualized-treatment-rules
#3
Emily L Butler, Eric B Laber, Sonia M Davis, Michael R Kosorok
Precision medicine seeks to provide treatment only if, when, to whom, and at the dose it is needed. Thus, precision medicine is a vehicle by which healthcare can be made both more effective and efficient. Individualized treatment rules operationalize precision medicine as a map from current patient information to a recommended treatment. An optimal individualized treatment rule is defined as maximizing the mean of a pre-specified scalar outcome. However, in settings with multiple outcomes, choosing a scalar composite outcome by which to define optimality is difficult...
July 25, 2017: Biometrics
https://www.readbyqxmd.com/read/28741387/baseline-characteristics-and-treatment-patterns-of-patients-with-schizophrenia-initiated-on-once-every-three-month-paliperidone-palmitate-in-the-real-world-setting
#4
Kruti Joshi, Marie-Hélène Lafeuille, Brianne Brown, Willy Wynant, Bruno Emond, Patrick Lefebvre, Neeta Tandon
OBJECTIVES: Since May 2015, adult patients with schizophrenia adequately treated with once-monthly paliperidone palmitate (PP1M) may be transitioned to once-every-three-month paliperidone palmitate (PP3M). This study aims to describe baseline characteristics and treatment patterns of patients with schizophrenia initiated on PP3M in the real-world setting. METHODS: Pharmacy and medical claims from 05/2014-09/2016 for adult patients with schizophrenia initiated on PP3M (index date) in the Symphony Health Solutions database were analyzed...
July 25, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28740827/self-versus-informant-reports-on-the-specific-levels-of-functioning-scale-relationships-to-depression-and-cognition-in-schizophrenia-and-schizoaffective-disorder
#5
Julia Ermel, Cameron S Carter, James M Gold, Angus W MacDonald, J Daniel Ragland, Steven M Silverstein, Milton E Strauss, Deanna M Barch
The goal of the current study was to examine the relationships between insight and both cognitive function and depression in schizophrenia and schizoaffective disorder, and to determine if there were similar relationships across diagnostic categories. We examined discrepancies between self and informant reports of function on the Specific levels of function scale as a metric of insight for interpersonal, social acceptance, work and activities. We examined two samples of individuals with schizophrenia and/or schizoaffective disorder (Ns of 188 and 67 respectively)...
September 2017: Schizophrenia Research. Cognition
https://www.readbyqxmd.com/read/28740825/nmdar-hypofunction-and-somatostatin-expressing-gabaergic-interneurons-and-receptors-a-newly-identified-correlation-and-its-effects-in-schizophrenia
#6
REVIEW
Fatemah Alherz, Mohammad Alherz, Hashemiah Almusawi
This review investigates the association between N-methyl-d-Aspartate receptor (NMDAR) hypofunction and somatostatin-expressing GABAergic interneurons (SST +) and how it contributes to the cognitive deficits observed in schizophrenia (SZ). This is based on evidence that NMDAR antagonists caused symptoms resembling SZ in healthy individuals. NMDAR hypofunction in GABAergic interneurons results in the modulation of the cortical network oscillation, particularly in the gamma range (30-80 Hz). These gamma-band oscillation (GBO) abnormalities were found to lead to the cognitive deficits observed in the disorder...
June 2017: Schizophrenia Research. Cognition
https://www.readbyqxmd.com/read/28740811/change-in-daytime-sleepiness-and-cognitive-function-in-a-6-month-double-blind-study-of-lurasidone-and-quetiapine-xr-in-patients-with-schizophrenia
#7
Philip D Harvey, Cynthia O Siu, Antony D Loebel
Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive performance during a 6-month, double-blind continuation study, in subjects who completed an initial 6-week, randomized, placebo-controlled trial comparing these agents. Daytime sleepiness, cognitive performance, and health-related quality of life were assessed with the Epworth Sleepiness Scale (ESS), CogState computerized battery, and the Quality of Well-Being (QWB-SA) Scale, respectively...
September 2016: Schizophrenia Research. Cognition
https://www.readbyqxmd.com/read/28740637/antipsychotic-induced-hyperprolactinemia-in-tourette-syndrome
#8
REVIEW
Judith J G Rath, Marlies E J Deen, Hessel van Houten, Sebastiaan F T M de Bruijn, Joop van Gerven, Dick Mul
For many years, Tourette syndrome (TS) was considered to be a rare disorder, but tics and TS are now recognized as fairly common childhood-onset conditions. Children and adolescents with TS are frequently treated with antipsychotics, either as monotherapy or in combination with psychostimulants, melatonin and selective serotonin reuptake inhibitors (SSRIs). Antipsychotics are most often used in schizophrenia and related psychotic disorders, and in these conditions hyperprolactinemia is one of the most common adverse effects associated with antipsychotics, occurring in 40-50% of patients...
July 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28740470/manual-dexterity-in-schizophrenia-a-neglected-clinical-marker
#9
Maxime Térémetz, Loïc Carment, Lindsay Brénugat-Herne, Marta Croca, Jean-Pierre Bleton, Marie-Odile Krebs, Marc A Maier, Isabelle Amado, Påvel G Lindberg
Impaired manual dexterity is commonly observed in schizophrenia. However, a quantitative description of key sensorimotor components contributing to impaired dexterity is lacking. Whether the key components of dexterity are differentially affected and how they relate to clinical characteristics also remains unclear. We quantified the degree of dexterity in 35 stabilized patients with schizophrenia and in 20 age-matched control subjects using four visuomotor tasks: (i) force tracking to quantify visuomotor precision, (ii) sequential finger tapping to measure motor sequence recall, (iii) single-finger tapping to assess temporal regularity, and (iv) multi-finger tapping to measure independence of finger movements...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/28739149/oral-medication-for-agitation-of-psychiatric-origin-a-scoping-review-of-randomized-controlled-trials
#10
Samuel Mullinax, Farhad Shokraneh, Michael P Wilson, Clive E Adams
BACKGROUND: Understanding more about the efficacy and safety of oral second-generation antipsychotic medications in reducing the symptoms of acute agitation could improve the treatment of psychiatric emergencies. OBJECTIVE: The objective of this scoping review was to examine the evidence base underlying expert consensus panel recommendations for the use of oral second-generation antipsychotics to treat acute agitation in mentally ill patients. METHODS: The Cochrane Schizophrenia Group's Study-Based Register was searched for randomized controlled trials comparing oral second-generation antipsychotics, benzodiazepines, or first-generation antipsychotics with or without adjunctive benzodiazepines, irrespective of route of administration of the drug being compared...
July 21, 2017: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28738259/reasons-associated-with-treatment-non-adherence-in-schizophrenia-in-a-pakistan-cohort
#11
Irshad Ahmad, Muhammad Tahir Khalily, Brian Hallahan
non-adherence in patients with schizophrenia is the most common reason for a relapse of psychosis. In a cohort of participants in Pakistan who suffered a relapse of psychosis, we aimed to identify the principal factors associated with non-adherence, including any culture specific factors that might not be as significant in other jurisdictions. Semi-structured interviews were undertaken at four psychiatric hospitals in the Peshawar region in Pakistan with 55 participants (44 male and 11 female) diagnosed with schizophrenia, who had suffered a relapse of psychosis subsequent to treatment non-adherence...
July 13, 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28737419/behavioral-activation-as-a-common-mechanism-of-change-across-different-orientations-and-disorders
#12
Giancarlo Dimaggio, Golan Shahar
Behavioral activation is an effective treatment for depression, based on targeting deprivation of positive rewards. It becomes more and more evident that many forms of mental disorders and psychological suffering involve reduction of goal-driven and pleasant activities. This reduction leaves negative mental states free to take the center of consciousness, without being counterbalanced by positive feelings, memories, and experiences of agency, self-efficacy, competence, relaxation, energy, and satisfaction. Reduced activity can be found in disorders ranging from chronic pain to personality disorders and schizophrenia...
July 24, 2017: Psychotherapy
https://www.readbyqxmd.com/read/28736102/antipsychotic-drugs-for-the-acute-treatment-of-patients-with-a-first-episode-of-schizophrenia-a-systematic-review-with-pairwise-and-network-meta-analyses
#13
Yikang Zhu, Marc Krause, Maximilian Huhn, Philipp Rothe, Johannes Schneider-Thoma, Anna Chaimani, Chunbo Li, John M Davis, Stefan Leucht
BACKGROUND: The first episode of schizophrenia is a pivotal phase of this debilitating illness. Which drug to use remains controversial without a summary of all direct or indirect comparisons of drugs. We did a systematic review with pairwise and network meta-analyses of efficacy and tolerability. METHODS: We searched MEDLINE, Embase, PsycINFO, Cochrane Library, PubMed, Biosis, and ClinicalTrials.gov for randomised controlled trials of antipsychotics for the acute treatment of first-episode schizophrenia, published up to Nov 17, 2016...
July 20, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28735641/risk-and-resilience-brain-networks-in-treatment-resistant-schizophrenia
#14
Eleni P Ganella, Caio Seguin, Cali F Bartholomeusz, Sarah Whittle, Chad Bousman, Cassandra M J Wannan, Maria A Di Biase, Christina Phassouliotis, Ian Everall, Christos Pantelis, Andrew Zalesky
BACKGROUND: Genes, molecules and neural circuits that are associated with, or confer risk to developing schizophrenia have been studied and mapped. It is hypothesized that certain neural systems may counterbalance familial risk of schizophrenia, and thus confer resilience to developing the disorder. This study sought to identify resting-state functional brain connectivity (rs-FC) representing putative risk or resilience endophenotypes in schizophrenia. METHODS: Resting-state functional magnetic resonance imaging (rs-fMRI) was performed in 42 individuals with treatment resistant schizophrenia (TRS), 16 unaffected first-degree family members (UFM) and 42 healthy controls...
July 20, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28734929/aripiprazole-prevents-renal-ischemia-reperfusion-injury-in-rats-probably-through-nitric-oxide-involvement
#15
Hanieh Gholampour, Leila Moezi, Hamed Shafaroodi
Renal ischemia/reperfusion (I/R) injury is strongly related to morbidity and mortality. Oxidative stress, inflammation, and apoptosis play key roles in renal dysfunction following renal I/R. Aripiprazole is an atypical antipsychotic which used for the treatment of schizophrenia and bipolar disorder. Recent studies have reported aripiprazole as displaying certain anti-inflammatory effects. Regarding the underlying mechanisms of renal ischemia-reperfusion, therefore, nephroprotective effects might be predicted to be seen with aripiprazole...
July 19, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28734907/predicting-relapse-in-schizophrenia-is-bdnf-a-plausible-biological-marker
#16
Anilkumar Pillai, Nina R Schooler, Diya Peter, Stephen W Looney, Donald C Goff, Alexander Kopelowicz, John Lauriello, Theo Manschreck, Alan Mendelowitz, Del D Miller, Joanne B Severe, Daniel R Wilson, Donna Ames, Juan Bustillo, John M Kane, Peter F Buckley
Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study...
July 19, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28734239/stigma-resistance-and-its-association-with-internalised-stigma-and-psychosocial-outcomes-among-psychiatric-outpatients
#17
Ying Wen Lau, Louisa Picco, Shirlene Pang, Anitha Jeyagurunathan, Pratika Satghare, Siow Ann Chong, Mythily Subramaniam
Studies have suggested that stigma resistance plays an important role in the recovery from mental illness. However, there has been limited research in Asian countries that has examined the benefits of stigma resistance among the mentally ill in Asian populations. Hence, this study aimed to assess the prevalence of stigma resistance and establish the socio-demographic correlates of stigma resistance, as well as its association with internalised stigma and psychosocial outcomes among a multi-ethnic population of 280 outpatients with obsessive compulsive disorder (OCD), schizophrenia, depressive disorders and anxiety disorders in Singapore...
July 14, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28734198/length-of-stay-for-25-791-california-patients-found-incompetent-to-stand-trial
#18
Matthew Renner, Carol Newark, Bradley J Bartos, Richard McCleary, Nicholas Scurich
Referrals and admissions to state psychiatric hospitals of criminal defendants found Incompetent to Stand Trial (IST) are on the rise in the state of California and other parts of the country. Studies of treatment outcomes of this population have primarily focused on factors that determine competency and/or restorability. However, as IST patients place an increasing resource burden on state psychiatric hospital systems, other outcomes such as length of stay (LOS) are becoming increasingly important for practitioners and policy makers to understand...
July 6, 2017: Journal of Forensic and Legal Medicine
https://www.readbyqxmd.com/read/28733707/angiotensin-ii-type-1-receptor-blockers-inhibit-kat-ii-activity-in-the-brain-its-possible-clinical-applications
#19
Izabela Zakrocka, Katarzyna M Targowska-Duda, Artur Wnorowski, Tomasz Kocki, Krzysztof Jóźwiak, Waldemar A Turski
Angiotensin II receptor blockers (ARBs) are one of the most frequently recommended antihypertensive drugs. Apart from their activity towards the circulatory system, ARBs also penetrate the blood-brain barrier and display neuroprotective effects. Kynurenic acid (KYNA) is an endogenous metabolite of tryptophan produced by kynurenine aminotransferase II (KAT II) in the brain. Antagonism towards all ionotropic glutamate (GLU) receptors is the main mechanism of KYNA action. An elevated brain level of KYNA is linked with memory impairment and psychotic symptoms...
July 21, 2017: Neurotoxicity Research
https://www.readbyqxmd.com/read/28732482/treatment-outcomes-in-schizophrenia-qualitative-study-of-the-views-of-family-carers
#20
Joanne Lloyd, Helen Lloyd, Ray Fitzpatrick, Michele Peters
BACKGROUND: Schizophrenia is a complex, heterogeneous disorder, with highly variable treatment outcomes, and relatively little is known about what is important to patients. The aim of the study was to understand treatment outcomes informal carers perceive to be important to people with schizophrenia. METHOD: Qualitative interview study with 34 individuals and 8 couples who care for a person with schizophrenia/schizoaffective disorder. Interviews were transcribed verbatim and analysed by a thematic framework based approach...
July 21, 2017: BMC Psychiatry
keyword
keyword
50210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"